Infliximab in treatment of idiopathic refractory childhood pyoderma gangrenosum (PG)
| Autor: | Yousef Mohammadikebar, Omid Ghanbarpour, Mehrdad Mirzarahimi, Afsaneh Enteshary, Farhad Salehzadeh |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
musculoskeletal diseases
medicine.medical_specialty business.industry Gastroenterology Disease medicine.disease Dermatology Infliximab Oncology Rheumatology Refractory Full recovery medicine Immunology and Allergy Pharmacology (medical) skin and connective tissue diseases business Pyoderma gangrenosum medicine.drug |
| Zdroj: | Biologics: Targets and Therapy. 13:97-99 |
| ISSN: | 1177-5491 |
| DOI: | 10.2147/btt.s203753 |
| Popis: | We report a case of refractory idiopathic childhood pyoderma gangrenosum in a young boy who had suffered from this disease since 3 years of age. He had unfavorable responses and intermittent relapses under different combinations of cytotoxic and steroid therapies. Although there was not much information available about infliximab use for biologic and childhood pyoderma gangrenosum, eventually we decided to use infliximab in this patient. Infliximab showed a dramatic response and resulted in full recovery during 2 years' follow-up. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|